

TREC Core publications 2025

1. **Antoun C**, Oto J, Morelli VM, Hveem K, **Braekkan SK**, Medina P, **Hansen JB**. Plasma miR-145-5p Levels and Risk of Future Cancer-Results from the HUNT Study. *Int J Mol Sci*. 2025; **26**. 10.3390/ijms26052191.
2. **Antoun C**, **Wikan VE**, Overli O, Ueland T, Yeganeh GJ, **Braekkan SK**, Brodin E, **Hansen JB**. Plasma microRNA-145-5p as a diagnostic biomarker for acute deep vein thrombosis. *Res Pract Thromb Haemost*. 2025; **9**: 102671. 10.1016/j.rpth.2024.102671.
3. **Braekkan SK**, **Onsaker AL**, Nost TH, Tang W, **Hindberg KD**, **Morelli VM**, Guan W, Jonasson C, Folsom AR, Hveem K, **Hansen JB**. The Plasma Proteome and Risk of Future Venous Thromboembolism-Results from the HUNT Study. *Thromb Haemost*. 2025; **125**: 574-84. 10.1055/a-2484-0836.
4. **Damoah CE**, **Valderhaug SM**, **Snir O**, **Hindberg KD**, **Braekkan SK**, Grover SP, Nost TH, Gal P, Pal G, Jonasson C, Garred P, Mollnes TE, Hveem K, **Hansen JB**. Elevated Plasma MBL Levels Are Associated With Risk of Future Venous Thromboembolism: The HUNT Study. *Arterioscler Thromb Vasc Biol*. 2025; **45**: e324-e35. 10.1161/ATVBAHA.124.322052.
5. de Winter MA, Cohen AT, **Hansen JB**, Kaasjager KAH, Kakkar AK, Middeldorp S, Sorensen HT, Visseren FLJ, Wells PS, Dorresteijn JAN, Nijkeuter M. "Risk assessment tools for bleeding in patients with unprovoked venous thromboembolism: an analysis of the PLATO-VTE study": comment. *J Thromb Haemost*. 2025; **23**: 3746-8. 10.1016/j.jtha.2024.12.018.
6. **Edvardsen MS**, **Hansen ES**, **Ueland T**, **Latysheva N**, Aukrust P, **Snir O**, **Morelli VM**, **Hansen JB**. Effect of plasma levels of factor VIII according to procoagulant phospholipids on the risk of future venous thromboembolism. *Res Pract Thromb Haemost*. 2025; **9**: 102636. 10.1016/j.rpth.2024.102636.
7. **Eide NH**, **Langholm C**, **Rinde FB**, Van Es N, Hveem K, **Braekkan SK**, **Hansen JB**, **Morelli VM**. Mortality risk after cancer-related venous thromboembolism has decreased over the last three decades: the HUNT and Tromso studies. *Haematologica*. 2025; **110**: 1328-38. 10.3324/haematol.2024.286407.
8. **Hald EM**, Lochen ML, Hveem K, Cushman M, **Braekkan SK**, **Hansen JB**. Joint effects of atrial fibrillation and prothrombotic genotypes on the risk of venous thromboembolism. *Res Pract Thromb Haemost*. 2025; **9**: 102880. 10.1016/j.rpth.2025.102880.
9. **Hald EM**, Lochen ML, Mathiesen EB, Hveem K, **Braekkan SK**, **Hansen JB**. Joint effects of atrial fibrillation and prothrombotic genotypes on the risk of ischemic stroke. *J Thromb Haemost*. 2025; **23**: 1401-6. 10.1016/j.jtha.2024.12.022.
10. **Hosseini M**, **Hindberg KD**, Nost TH, Jonasson C, Hveem K, **Hansen JB**, **Snir O**. Plasma osteopontin levels are associated with the risk of future incident venous thromboembolism-the Trondelag Health Study (HUNT). *J Thromb Haemost*. 2025; **23**: 2849-57. 10.1016/j.jtha.2025.04.020.
11. **Johansson M**, **Braekkan SK**, Giskeodegard GF, Wade KH, **Hindberg KD**, Timpson N, Davey Smith G, Hveem K, Asvold BO, Brumpton BM, **Hansen JB**. High concentrations of polyunsaturated n-3 fatty acids in serum are inversely associated with risk of future incident venous thromboembolism - the HUNT cohort study. *Am J Clin Nutr*. 2025; **122**: 1195-203. 10.1016/j.ajcnut.2025.08.008.
12. **Langholm C**, **Eide NH**, Hveem K, van Es N, **Braekkan SK**, **Morelli VM**, **Hansen JB**. Risk of Cancer in the Short and Long Term after Incident Venous Thromboembolism: The HUNT and Tromso Studies. *Thromb Haemost*. 2025. 10.1055/a-2679-6152.

13. **Leknessund OGR, Hansen JB, Braekkan SK.** Resting Heart Rate and Risk of Incident Venous Thromboembolism: The Tromso Study. *Thromb Haemost.* 2025. 10.1055/a-2593-1679.
14. **Løchen Arnesen CA,** Hveem K, Gabrielsen ME, **Hansen JB, Braekkan SK.** Body height and risk of venous thromboembolism in men vs women. *J Thromb Haemost.* 2025; **23**: 1576-84. 10.1016/j.jtha.2025.02.006.
15. Munsch G, Mohapatra AK, van Hylckama Vlieg A, Kleber ME, Martinez-Perez A, Le NQ, **Hindberg KD,** Dusart P, Germain M, Thibord F, Deleuze JF, Delgado GE, Goumidi L, Suchon P, Saut N, Souto JC, Butler LM, Soria JM, **Hansen JB,** Marz W, Rosendaal FR, Castoldi E, Peiretti F, Sabater-Lleal M, Tregouet DA, Morange PE. A multiomics approach reveals novel regulators of plasma factor V levels, highlighting CLEC4M as a clearance receptor. *Blood.* 2025; **146**: 628-37. 10.1182/blood.2024027006.
16. **Olsen MM, Braekkan SK,** Hveem K, Gronning K, **Hansen JB.** Repeated measures of coffee consumption and risk of future incident venous thromboembolism-the Trondelag Health Study and the Tromso study. *Res Pract Thromb Haemost.* 2025; **9**: 103019. 10.1016/j.rpth.2025.103019.
17. **Onsaker AL, Arntzen AY,** Tregouet DA, Nost TH, Tang W, Guan W, Jonasson C, Morange PE, Hindberg KD, Folsom AR, Hveem K, **Morelli VM, Hansen JB.** Histo-blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study. *Blood.* 2025; **145**: 2656-65. 10.1182/blood.2024025923.
18. **Tondel BG, Morelli VM,** Mathiesen EB, Lochen ML, Wilsgaard T, Hveem K, **Hansen JB, Braekkan SK.** Impact of ischemic stroke on the risk of venous thromboembolism in the general population: the Tromso Study and the Trondelag Health Study. *J Thromb Haemost.* 2025; **23**: 3307-18. 10.1016/j.jtha.2025.07.008.
19. **Wikan VE,** Overli O, **Ueland T,** Mollnes TE, **Braekkan SK,** Michelsen AE, Yeganeh GJ, **Hansen JB,** Brodin EE. Complement activation assessed by C3bc and C5b-9 terminal complex as diagnostic biomarkers for deep vein thrombosis. *PloS one.* 2025; **20**: e0333206. 10.1371/journal.pone.0333206.
20. **Xavier S, Wikan VE,** Wahlund CJE, **Latysheva N,** Overli O, **Antoun C, Ueland T,** Yeganeh GJ, **Braekkan SK, Hansen JB,** Brodin E, **Snir O.** Total and extracellular vesicle-bound plasma P-selectin as diagnostic biomarkers for acute deep vein thrombosis. *Res Pract Thromb Haemost.* 2025; **9**: 103171. 10.1016/j.rpth.2025.103171.